Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

Valo Health is eligible for a further $1.9 billion in potential milestone payments for up to nine new drug programs "Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact -- Update," at ...

The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 8 unusual trades. Delving into the details, we found 50% of ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro ... While all state Medicaid programs include GLP-1s prescribed for Type 2 diabetes ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

I’m bullish on Novo Nordisk based on its suddenly appealing valuation, consistent track record as a dividend stock, and long-term history of outperforming the market. For patient investors ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...